Year: 2017

Synbiobeta: PvP takes a nontraditional path to early stage drug development and financing

May 1, 2017

Winning iGEM award was just the beginning The KumaMax project got its start in 2011 as an undergraduate project at the University of Washington (UW) for the international Genetically Engineered Machine (iGEM) competition. The iGEM competition is the premiere student team competition in synthetic biology. The 2011 UW iGEM team entered a computer-generated protein design to combat…

Read More

Ozy News: How Designer Proteins Could Change Your Life

March 8, 2017

Ozy News spoke with Drs. David Baker and Ingrid Swanson Pultz about using Rosetta, a computer software program, to design novel proteins, like KumaMax. KumaMax is a uniquely engineered, recombinant enzyme that is designed to be active under acidic stomach conditions and has high specificity for the parts of gluten that trigger the autoimmune reaction leading…

Read More

In the News: PvP Biologics and Takeda Deal

January 6, 2017

In a unique deal, PvP Biologics skipped venture funding and brought on pharma partner Takeda in a $35 million agreement to advance a therapeutic candidate, called KumaMax, for celiac disease into clinical trials. In an interview with MedCity News, President and CEO Adam Simpson said the collaboration arms the startup with the financing and freedom needed…

Read More

Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

January 5, 2017

Osaka, Japan, January 6, 2017, San Diego, Calif., USA, and Seattle, Wash., USA, January 5, 2017 – Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby…

Read More

PvP Biologics Announces Leadership Team

January 5, 2017

SAN DIEGO and SEATTLE, January 5 – PvP Biologics today announced the company’s leadership team. The company was formed to advance an oral enzyme therapy, called KumaMax, for the treatment of celiac disease. Currently in pre-clinical development, KumaMax is a uniquely engineered, recombinant enzyme that is active under acidic stomach conditions and has high specificity…

Read More